Oivind G. Torkildsen
Bergen, 5020, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.
Journal: Science translational medicine
Published: July 15, 2026
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
Journal: The New England journal of medicine
Published: July 01, 2026
Misleading presentation of the evidence base for MS treatment
Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
Published: January 20, 2026
Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study.
Journal: BMJ neurology open
Published: January 13, 2026
Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study.
Journal: Frontiers in neurology
Published: January 08, 2026
Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: November 25, 2025
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: November 04, 2025
Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis.
Journal: Clinical pharmacokinetics
Published: October 07, 2025
Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.
Journal: Neurology and therapy
Published: October 03, 2025
Normative Modelling of Brain Volume in Multiple Sclerosis.
Journal: medRxiv : the preprint server for health sciences
Published: September 26, 2025
Last Updated: 09/26/2026